Scinai Immunotherapeutics (SCNI) Accounts Payables (2016 - 2025)

Scinai Immunotherapeutics has disclosed Accounts Payables across 10 years of filings, most recently posting $544000.0 for Q4 2025.

• Accounts Payables for Q4 2025 came in at $544000.0, up 44.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $544000.0 (up 44.68% YoY), and the FY2025 annual result was $544000.0, up 44.68% from the prior year.
• Accounts Payables came in at $544000.0 for Q4 2025 at Scinai Immunotherapeutics, down from $659000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.6 billion in Q2 2021 to a low of $297000.0 in Q3 2022.
• The 5-year median for Accounts Payables is $687500.0 (2022), against an average of $262.9 million.
• Across the five-year window, Accounts Payables sank 99.98% in 2022 and jumped 83.84% in 2023, its largest moves.
• Scinai Immunotherapeutics' Accounts Payables stood at $999000.0 in 2021, then decreased by 28.33% to $716000.0 in 2022, then increased by 18.58% to $849000.0 in 2023, then slumped by 55.71% to $376000.0 in 2024, then surged by 44.68% to $544000.0 in 2025.
• The last three Accounts Payables figures came in at $544000.0 (Q4 2025), $659000.0 (Q2 2025), and $376000.0 (Q4 2024), per Business Quant data.